1. Home
  2. AUTL vs PCRX Comparison

AUTL vs PCRX Comparison

Compare AUTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

N/A

Current Price

$2.10

Market Cap

596.2M

Sector

Health Care

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$25.82

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AUTL
PCRX
Founded
2014
2006
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.2M
1.1B
IPO Year
2025
2010

Fundamental Metrics

Financial Performance
Metric
AUTL
PCRX
Price
$2.10
$25.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$8.50
$30.25
AVG Volume (30 Days)
2.6M
415.8K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.19
Revenue
$10,120,000.00
$541,533,000.00
Revenue This Year
$80.32
$6.78
Revenue Next Year
$53.96
$8.54
P/E Ratio
N/A
$136.16
Revenue Growth
496.00
26.04
52 Week Low
$1.18
$18.80
52 Week High
$2.58
$27.66

Technical Indicators

Market Signals
Indicator
AUTL
PCRX
Relative Strength Index (RSI) 45.92 50.12
Support Level $1.37 $24.61
Resistance Level $2.43 $26.94
Average True Range (ATR) 0.10 0.61
MACD -0.06 0.08
Stochastic Oscillator 3.23 56.00

Price Performance

Historical Comparison
AUTL
PCRX

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: